MNX1: A Drug Target / Disease Biomarker (G3110)

Target Name: MNX1

NCBI ID: G3110

MNX1

MNX1: A Drug Target / Disease Biomarker

MNX1, also known as melanoma nuclear factor (MNF), is a protein that is expressed in a variety of tissues, including the skin, hair, and brain. It has been shown to play a role in the development and progression of melanoma, one of the most aggressive forms of skin cancer. Therefore, MNX1 has become a focus of interest for researchers as a potential drug target or biomarker.

MNX1 is a cytoplasmic protein that is composed of 251 amino acid residues. It has a molecular weight of 31 kDa and a pre-fusion protein of 28 kDa. MNX1 is predominantly expressed in the cytoplasm of cultured cells, and its levels vary depending on the type of cell and the conditions in which it is cultured.

MNX1 is involved in a variety of cellular processes that are important for normal cell growth and development. One of its functions is to regulate the growth and differentiation of cells. It has been shown to play a role in the regulation of cell proliferation, cell adhesion, and cell migration. MNX1 has also been shown to promote the formation of new blood vessels in wound healing, which is important for the recruitment of immune cells to the site of injury.

In addition to its functions in cellular processes, MNX1 has also been shown to play a role in the development and progression of cancer. Its expression has been observed in a variety of tissues, including the skin, hair, and brain, and has been implicated in the development of melanoma, breast cancer, and other cancers. Therefore, MNX1 has become a focus of interest for cancer researchers as a potential drug target or biomarker.

One of the challenges in studying MNX1 is its relatively high expression in a variety of tissues, which can make it difficult to study its effects in specific tissues. Additionally, the functions of MNX1 are not well understood, which can make it difficult to predict its potential therapeutic effects. However, research into MNX1 is ongoing, and there is a growing interest in using it as a drug target or biomarker for a variety of diseases.

In conclusion, MNX1 is a protein that is expressed in a variety of tissues and is involved in a variety of cellular processes. Its functions have been implicated in the development and progression of cancer, and it has become a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to fully understand the effects of MNX1 and its potential therapeutic uses.

Protein Name: Motor Neuron And Pancreas Homeobox 1

Functions: Transcription factor (By similarity). Recognizes and binds to the regulatory elements of target genes, such as visual system homeobox CHX10, negatively modulating transcription (By similarity). Plays a role in establishing motor neuron identity, in concert with LIM domain transcription factor LMO4 (By similarity). Involved in negatively modulating transcription of interneuron genes in motor neurons, acting, at least in part, by blocking regulatory sequence interactions of the ISL1-LHX3 complex (By similarity). Involved in pancreas development and function; may play a role in pancreatic cell fate specification (By similarity)

The "MNX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MNX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets